Skip to main content
IART logo

IART · Integra Lifesciences Holdings Corp · Webcasts, Transcripts & Audio

Track IART — free
Market Cap
$1.12B
Shares
77.80M
Volume · Nov 13 648.85K Avg daily vol (3M) 1.02M

Integra Lifesciences Holdings Corp Webcasts

Earnings calls, investor updates, investor days and conferences for Integra Lifesciences Holdings Corp (IART), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-10-21
Integra Lifesciences Holdings Corp (IART) Q3 2026 Earnings Call Transcript
Balanced tone Tissue reconstruction recovery Cincinnati manufacturing disruption Neurosurgery momentum
Revenue
$411.18M
▲ 2.3% YoY
Diluted EPS
$0.19
Gross margin
51.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-15
Integra Lifesciences Holdings Corp (IART) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-15
Integra Lifesciences Holdings Corp (IART) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Integra Lifesciences Holdings Corp (IART) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Integra Lifesciences Holdings Corp (IART) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-29
Integra Lifesciences Holdings Corp (IART) Q2 2026 Earnings Call Transcript
Positive tone Surgimend/Durazorb relaunch and PMA strategy Second quarter financial performance Tissue reconstruction and wound care
Revenue
$418.76M
▲ 0.8% YoY
Diluted EPS
$0.06
Gross margin
52.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-16
Integra Lifesciences Holdings Corp (IART) June 16, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Integra Lifesciences Holdings Corp (IART) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-12
Integra Lifesciences Holdings Corp (IART) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Integra Lifesciences Holdings Corp (IART) Q1 2026 Earnings Call Transcript
Positive tone Q1 Financial Results CEO Transition and Leadership Change Margins and Transformation
Revenue
$391.92M
▲ 2.4% YoY
Diluted EPS
$-0.06
Gross margin
55.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Integra Lifesciences Holdings Corp (IART) Q4 2025 Earnings Call Transcript
Positive tone 2026 financial guidance Portfolio segment performance (CSS and Tissue) International growth and China expansion
Revenue
$434.93M*
▼ 1.7% YoY
Gross margin
50.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Integra Lifesciences Holdings Corp (IART) Q3 2025 Earnings Call Transcript
Positive tone Product relaunches (PriMatrix and Durepair) Compliance Master Plan and FDA remediation Supply chain and operational execution
Revenue
$402.06M
▲ 5.6% YoY
Diluted EPS
$-0.07
Gross margin
51.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Integra Lifesciences Holdings Corp (IART) Q2 2025 Earnings Call Transcript
Positive tone Revenue and EPS Guidance Compliance Master Plan and Quality Remediation Braintree Facility and Product Relaunch
Revenue
$415.61M
▼ 0.6% YoY
Diluted EPS
$-6.31
Gross margin
50.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Integra Lifesciences Holdings Corp (IART) Q1 2025 Earnings Call Transcript
Cautious tone Tariffs and mitigation Organic vs. reported revenue growth Ship holds / supply disruption
Revenue
$382.65M
▲ 3.7% YoY
Diluted EPS
$-0.33
Gross margin
50.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Integra Lifesciences Holdings Corp (IART) Q4 2024 Earnings Call Transcript
Cautious tone Manufacturing and Supply Chain Recovery Portfolio Growth and Innovation Compliance Master Plan and FDA Remediation
Revenue
$442.65M*
▲ 11.5% YoY
Gross margin
56.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Integra Lifesciences Holdings Corp (IART) Q3 2024 Earnings Call Transcript
Cautious tone Supply Constraints and Revenue Impact 2025 Guidance and Share Recapture Quality and Compliance Master Plan
Revenue
$380.83M
▼ 0.4% YoY
Diluted EPS
$-0.14
▼ 158.3% YoY
Gross margin
52.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-29
Integra Lifesciences Holdings Corp (IART) Q2 2024 Earnings Call Transcript
Cautious tone Compliance master plan and quality systems remediation Acclarent integration and ENT franchise Tissue Technologies portfolio strength
Revenue
$418.18M
▲ 9.7% YoY
Diluted EPS
$-0.16
▼ 420% YoY
Gross margin
54.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Integra Lifesciences Holdings Corp (IART) Q1 2024 Earnings Call Transcript
Cautious tone Boston plant remediation and recall Guidance and financial outlook Acclarent acquisition and ENT expansion
Revenue
$368.87M
▼ 3.1% YoY
Diluted EPS
$-0.04
▼ 113.8% YoY
Gross margin
56.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Integra Lifesciences Holdings Corp (IART) Q4 2023 Earnings Call Transcript
Balanced tone Boston recall and manufacturing recovery Financial results and 2024 guidance International expansion and China strategy
Revenue
$397.04M*
▼ 0.2% YoY
Gross margin
57.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-25
Integra Lifesciences Holdings Corp (IART) Q3 2023 Earnings Call Transcript
Revenue
$382.42M
▼ 0.7% YoY
Diluted EPS
$0.24
▼ 60% YoY
Gross margin
57.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
Integra Lifesciences Holdings Corp (IART) Q2 2023 Earnings Call Transcript
Revenue
$381.27M
▼ 4.2% YoY
Diluted EPS
$0.05
▼ 90.7% YoY
Gross margin
54.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Integra Lifesciences Holdings Corp (IART) Q1 2023 Earnings Call Transcript
Revenue
$380.85M
▲ 1.1% YoY
Diluted EPS
$0.29
▼ 25.6% YoY
Gross margin
61.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-10
Integra Lifesciences Holdings Corp (IART) Q4 2022 Earnings Call Transcript
Revenue
$398.02M*
▼ 1.8% YoY
Gross margin
62.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Integra Lifesciences Holdings Corp (IART) Q3 2022 Earnings Call Transcript
Revenue
$385.19M
▼ 0.4% YoY
Diluted EPS
$0.60
▲ 17.6% YoY
Gross margin
61.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Integra Lifesciences Holdings Corp (IART) Q2 2022 Earnings Call Transcript
Revenue
$397.81M
▲ 2% YoY
Diluted EPS
$0.54
▲ 31.7% YoY
Gross margin
62.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Integra Lifesciences Holdings Corp (IART) Q1 2022 Earnings Call Transcript
Revenue
$376.64M
▲ 4.6% YoY
Diluted EPS
$0.39
▼ 26.4% YoY
Gross margin
62.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Integra Lifesciences Holdings Corp (IART) Q4 2021 Earnings Call Transcript
Revenue
$405.52M*
▲ 4.3% YoY
Gross margin
61.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Integra Lifesciences Holdings Corp (IART) Q3 2021 Earnings Call Transcript
Revenue
$386.86M
▲ 4.5% YoY
Diluted EPS
$0.51
▲ 34.2% YoY
Gross margin
62.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Integra Lifesciences Holdings Corp (IART) Q2 2021 Earnings Call Transcript
Revenue
$389.99M
▲ 50.8% YoY
Diluted EPS
$0.41
Gross margin
61.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Integra Lifesciences Holdings Corp (IART) Q1 2021 Earnings Call Transcript
Revenue
$360.07M
▲ 1.6% YoY
Diluted EPS
$0.53
▲ 381.8% YoY
Gross margin
59.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-14
Integra Lifesciences Holdings Corp (IART) Q4 2020 Earnings Call Transcript
Revenue
$388.65M
▼ 1.6% YoY
Diluted EPS
$1.09
▲ 505.6% YoY
Gross margin
62.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-06
Integra Lifesciences Holdings Corp (IART) Q3 2020 Earnings Call Transcript
Revenue
$370.23M
▼ 2.3% YoY
Diluted EPS
$0.38
Gross margin
63.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-09
Integra Lifesciences Holdings Corp (IART) Q2 2020 Earnings Call Transcript
Revenue
$258.67M
▼ 32.6% YoY
Diluted EPS
$0.00
▼ 100% YoY
Gross margin
59.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-07
Integra Lifesciences Holdings Corp (IART) Q1 2020 Earnings Call Transcript
Revenue
$354.32M
▼ 1.5% YoY
Diluted EPS
$0.11
▼ 71.1% YoY
Gross margin
62.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-14
Integra Lifesciences Holdings Corp (IART) Q4 2019 Earnings Call
Revenue
$395.13M
▲ 3.1% YoY
Diluted EPS
$0.18
▼ 37.9% YoY
Gross margin
62.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–35 of 35 webcasts
Key facts CIK 917520 CUSIP 457985208 13F (30d) 187 filings 166 filers Visit website Investor relations